TAZICEF
Approved
Approval ID
40d48c5d-650e-461b-a67b-7e65772d1b92
Product Type
HUMAN PRESCRIPTION DRUG LABEL
Effective Date
Mar 10, 2023
Manufacturers
FDA
Hospira, Inc.
DUNS: 141588017
Products 2
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
CEFTAZIDIME
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code0409-5082
Application NumberANDA062662
Product Classification
M
Marketing Category
C73584
G
Generic Name
CEFTAZIDIME
Product Specifications
Route of AdministrationINTRAMUSCULAR, INTRAVENOUS
Effective DateMarch 10, 2023
FDA Product Classification
INGREDIENTS (2)
CEFTAZIDIMEActive
Quantity: 1 g in 1 1
Code: 9M416Z9QNR
Classification: ACTIM
SODIUM CARBONATEInactive
Quantity: 118 mg in 1 1
Code: 45P3261C7T
Classification: IACT
CEFTAZIDIME
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
NDC Product Code0409-5084
Application NumberANDA062662
Product Classification
M
Marketing Category
C73584
G
Generic Name
CEFTAZIDIME
Product Specifications
Route of AdministrationINTRAVENOUS
Effective DateMarch 10, 2023
FDA Product Classification
INGREDIENTS (2)
CEFTAZIDIMEActive
Quantity: 2 g in 1 1
Code: 9M416Z9QNR
Classification: ACTIM
SODIUM CARBONATEInactive
Quantity: 236 mg in 1 1
Code: 45P3261C7T
Classification: IACT